Cardiovascular

During an industry workshop at the Academy of Managed Care Pharmacy Annual Meeting in Denver, Colorado, Cliff Goodman, PhD, of the Lewin Group, moderated a session that provided a health economic case study on cardiovascular outcome data for Repatha (evolocumab), the PCSK9 inhibitor from Amgen.

According to Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine, research on rivaroxaban to prevent thrombosis is moving from determining efficacy to evaluating patient-centered outcomes in a variety of clinical situations, as evidenced by new studies like EINSTEIN-CHOICE and the MARINER trial.

The study found a "dose effect" in the elderly women who took statins to treat cholesterol.

The drop in mortality was driven by a significant drop in cardiovascular mortality, the leading cause of death among seniors.

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.

An author in JAMA points out some caveats to a ground-breaking trial.

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March 2017 at the American College of Cardiology 66th Scientific Sessions.

Busy lifestyles are eroding the lines of traditional meal times, and all-day eating is bad for cardiovascular health, the statement says.

The study found only tobacco use and hypertension were worse on the heart than depression.

The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions.

Researchers considered finding a diabetes drug that also produced a cardiovascular benefit to be a "holy grail."

The matchstick-size pump has been heralded as a game changer in addressing the biggest problem in diabetes care: medication adherence.

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.

A new study suggests pollution particles could set into motion events like heart attacks and strokes years before they occur.

While the researchers found a "modest risk" of diabetes associated with job insecurity, they said it pointed to the need for policies that promoted job stability and better wages.

The Jackson Heart Study continues to yield insights about the nature of cardiovascular disease in minority populations.

Whether it’s the high cost of insulin or the question of when to start combination therapy, the new issue of Evidence-Based Diabetes Management, a publication of The American Journal of Managed Care, covers up-to-the-minute topics in this special issue on therapeutics. Editor-in-chief Robert A. Gabbay, MD, PhD, FACP, leads off this issue featuring voices of providers, pharmaceutical leaders, payers, and patients.

Second of 2 Parts: See Part 1, in Evidence-Based Diabetes Management, coverage of Patient-Centered Diabetes Care 2016.

Results for Novo Nordisk’s semaglutide were reported today at the European Association for the Study of Diabetes. A filing for FDA approval is expected before the end of the year.

The authors said this is the first study to examine antihypertension nonadherence down to the county level. Recommendations include greater use of combination therapy to reduce pill counts for patients with multiple chronic conditions, and synchronizing pharmacy visits to avoid multiple trips.

While the online tools makes clear consumers can use it without obligation, the therapy section give patients information on AstraZeneca products.

Although team-based care improved cardiovascular disease risk factors, it had a negative financial impact on a primary care practice.

Two consultants who help stakeholders in value-based transitions say CMS is serious about an aggressive pace for payment reform.

The approval paves the way for Sanofi's insulin and GLP-1 combination therapy, which is due for final FDA action in August.